Genematrix said Wednesday it obtained a patent for a “Protein REFolding EnhanceR” (PREFER) technology - a key for the mass production of recombinant proteins.

Recombinant proteins are used as active pharmaceutical ingredients (API) for new protein drugs. Excessive recombinant proteins produced from genetic recombination techniques often convert to insoluble complexes and lose biological activity and medical efficacy.

The patented technology can boost medical applications through efficient solubilization of recombinant proteins, ensuring both productivity and efficacy of protein materials for medical use, Genematrix said.

“Technology that maintains drug efficacy is essential to successfully develop new protein-based drugs that use recombinant proteins as active ingredients,” a company official said. “We plan to utilize this patented technology, which can be universally applied to various protein drugs, to explore the efficacy of new drug substances as well as mass production.”

yjc@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>